MedTrace Logo

Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma

NCT01598038 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-07-28

No results posted yet for this study

Summary

The investigators hypothesize everolimus toxicities are linked to pharmacokinetic variabilities of everolimus. Thus, early detection of clinical or biological risk factors will lead to personalized dosage treatment and permit a better tolerance without altering efficacy.

Conditions

Interventions

OTHER

Blood sample

Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation

Sponsors & Collaborators

  • University Hospital, Caen

    collaborator OTHER

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • SEVIN Emmanuel, MD · Centre François Baclesse

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-03-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01598038 on ClinicalTrials.gov